Trial Profile
A Phase II Trial Of Gemcitabine in Combination With 17-Allylaminogeldamycin (17-AAG) In Advanced Epithelial Ovarian And Primary Peritoneal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Tanespimycin (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 25 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.